NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting

Data confirm bactericidal activity of NB-003 against P. acnes, suggest promise of nanoemulsions in topical acne therapy


 

ANN ARBOR, Mich.--(BUSINESS WIRE)--Jul 29, 2009 - NanoBio Corp. today announced that it will present compelling new data for NB-003, the company's nanoemulsion based clinical stage product for the treatment of acne. The information will be delivered orally and in poster format at the Academy of Dermatology Summer Meeting, taking place July 29-August 2nd at the Hynes Convention Center, Boston, Mass. Posters will be available for download during the meeting and from the NanoBio web site. The oral presentation schedule is as follows:


 

Poster Presentation # 106 - Thursday, July 30, 10:00 AM


 

 


 


  • Susceptibility of Propionibacterium acnes in the Presence of Sebum to NB-003 Formulations
     


 

Poster Presentation # 109 - Thursday, July 30, 10:30 AM


 

 


 


  • Novel Follicular-Targeted Nanoemulsion for Acne
     


 

About NB-003


 

NB-003 uniquely penetrates the skin and enters epidermal tissues targeting the oil producing glands connected to a hair follicle. This penetration results in effective delivery of the nanoemulsion droplets to the site of infection. These droplets disrupt the P. acnes and are cidal on contact. NB-003 and other NanoBio dermatological products are derived from NanoBio's patented NanoStat™ technology platform. NanoBio is currently conducting a Phase I study with NB-003.


 

About NanoBio


 

NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum, and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.


 

 


 

 


 

Contact: John Coffey, 734-302-9107

Vice President, Business Development

john.coffey@nanobio.com

or

Media Contacts:

Schwartz Communications

Andrea tenBroek / Laura Coluci

781-684-0770

nanobio@schwartz-pr.com


 

***


 

 

Posted: July 2009

View comments

Hide
(web1)